Traders Buy High Volume of Merck & Co., Inc. Call Options (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) saw unusually large options trading on Wednesday. Investors acquired 42,821 call options on the stock. This is an increase of approximately 42% compared to the average daily volume of 30,188 call options.

Institutional Trading of Merck & Co., Inc.

A number of hedge funds and other institutional investors have recently bought and sold shares of MRK. Hunter Associates Investment Management LLC lifted its stake in Merck & Co., Inc. by 15.3% in the 2nd quarter. Hunter Associates Investment Management LLC now owns 13,691 shares of the company’s stock worth $1,758,000 after purchasing an additional 1,817 shares in the last quarter. Ignite Planners LLC boosted its holdings in Merck & Co., Inc. by 5.4% in the 2nd quarter. Ignite Planners LLC now owns 7,223 shares of the company’s stock valued at $929,000 after purchasing an additional 368 shares during the period. Eaton Cambridge Inc. purchased a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at $225,000. Welch Group LLC grew its position in shares of Merck & Co., Inc. by 1.2% during the 2nd quarter. Welch Group LLC now owns 37,231 shares of the company’s stock valued at $4,784,000 after purchasing an additional 448 shares in the last quarter. Finally, Forum Financial Management LP grew its position in shares of Merck & Co., Inc. by 3.9% during the 2nd quarter. Forum Financial Management LP now owns 10,899 shares of the company’s stock valued at $1,401,000 after purchasing an additional 406 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Guggenheim upped their price objective on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a report on Monday, July 13th. Scotiabank lifted their target price on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, June 30th. Morgan Stanley boosted their price target on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. UBS Group upped their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $133.94.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $130.57 on Friday. The business’s fifty day moving average is $121.27 and its 200 day moving average is $117.62. The firm has a market cap of $322.49 billion, a price-to-earnings ratio of 36.78, a PEG ratio of 5.08 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $131.74.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Research analysts predict that Merck & Co., Inc. will post 2.74 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date was Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.